Clerk of the House of Representatives Secretary of the Senate Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY 02 AUG |

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

Cathy Abernathy Consultants			
2. Address Check if different than previously r	reported		
512 C Street, NE			
3. Principal Place of Business (if different from line 2)			
City: Washington	State/Zip (or Country) DC 20002	
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID#
Cathy Abernathy	(202) 266-3940	cabernathy@libertystar.net	691
7. Client Name			6. House ID#
Pharmaceutical Research Association (PHRMA)			
INCOME OR EXPENSES - (Complete Etitler L	13. Organizat	tions
INCOME relating to lobbying activities for this reporting		EXPENSES relating to lobbying activities for this reperiod were:	
period was: Less than \$10,000	-	Less than \$10,000 🗖	
\$10,000 or more	40,000.00	\$10,000 or more Expenses (nearest \$20,0) 14. REPORTING METHOD. Check box to indicat accounting method. See instructions for description o Method A. Reporting amounts using LDA defini Method B. Reporting amounts under section 60: Internal Revenue Code Method C. Reporting amounts under section 16: Internal Revenue Code	
\$10,000 or more Income (note income) Provide a good faith estimate, rounded to the of all lobbying related income from the clipayments to the registrant by any other eractivities on behalf of the client).	e nearest \$20,000, ient (including all ntity for lobbying	Method A. Reporting amounts us Method B. Reporting amounts us Internal Revenue Cod Method C. Reporting amounts us	t box to indicate or description of the LDA definition der section 603 to the latest section 16.
Provide a good faith estimate, rounded to the of all lobbying related income from the clipayments to the registrant by any other er	e nearest \$20,000, ient (including all ntity for lobbying	Method A. Reporting amounts us Method B. Reporting amounts us Internal Revenue Cod Method C. Reporting amounts us Internal Revenue Cod	k box to indicate or description of the LDA definition of the local description for the local de

Registrant Name	Cathy Abernathy Consultants	Client Name	Pharmaceutical Research Association (PHRN
engaged in lobbyi	FIVITY. Select as many cong on behalf of the client duplested. Attach additional p	iring the reporting peri	flect the general issue areas in which the iod. Using a separate page for each cod
15. General issue	area code HCR (o	ne per page)	
16. Specific lobb	ying issues ledicare Modernization and Pre	scription Drug Act of 2002	2
·			
17. House(s) of (Congress and Federal agenc	ies contacted	☐ Check if None
U.S. House	of Representatives		
18. Name of eac	h individual who acted as a	lobbyist in this issue a	covered Official Position (if applicable)
18. Name of eac	Name	lobbyist in this issue a	
	Name	lobbyist in this issue a	
	Name	lobbyist in this issue a	
	Name	lobbyist in this issue a	
	Name	lobbyist in this issue a	
	Name	lobbyist in this issue a	
	Name	lobbyist in this issue a	
	Name	lobbyist in this issue a	
Cathy Abernathy	Name		Covered Official Position (if applicable)

Form LD-2 (Rev.6/98)

00020292979

Registrant Name	Cathy Abernathy Consultants	Client Name	Pharmaceutical Research Association (PHRM
engaged in lobbying	FIVITY. Select as many codes ng on behalf of the client during uested. Attach additional page	g the reporting pe	eflect the general issue areas in which the r riod. Using a separate page for each code
15. General issue	area code PHA (one p	er page)	
H.R. 4954 M	ying issues edicare Modernization and Prescrip	ition Drug Act of 20	02
17 House(s) of (Congress and Federal agencies o	contacted	Check if None
	of Representatives a individual who acted as a lobb	oyist in this issue	area
	Name		Covered Official Position (if applicable)
Cathy Abernathy	•		
19. Interest of eac	h foreign entity in the specific issu	es listed on line 16	above Check if None
Signature	Atty all Title Cathy Abernathy, Presider	wash	1 Date 8/14/02

Form LD-2 (Rev.6/98)